2.99 USD
+0.09
3.10%
Updated Feb 7, 12:08 PM EST
1 day
3.10%
5 days
7.94%
1 month
-4.47%
3 months
-12.06%
6 months
-14.57%
Year to date
-1.97%
1 year
-54.35%
5 years
-99.48%
10 years
-99.48%
 

About: PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.

Employees: 62

0
Funds holding %
of 6,831 funds
Analysts bullish %

Fund manager confidence

Based on 2024 Q3 regulatory filings by fund managers ($100M+ AUM)

33% more funds holding

Funds holding: 9 [Q2] → 12 (+3) [Q3]

28% more capital invested

Capital invested by funds: $5.19M [Q2] → $6.64M (+$1.46M) [Q3]

14.88% more ownership

Funds ownership: 25.17% [Q2] → 40.05% (+14.88%) [Q3]

0% more repeat investments, than reductions

Existing positions increased: 3 | Existing positions reduced: 3

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

Low target
$11
268%
upside
Avg. target
$11
268%
upside
High target
$11
268%
upside

1 analyst rating

positive
100%
neutral
0%
negative
0%
HC Wainwright & Co.
Raghuram Selvaraju
40% 1-year accuracy
130 / 329 met price target
268%upside
$11
Buy
Maintained
26 Dec 2024

Financial journalist opinion

Neutral
GlobeNewsWire
1 week ago
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
PETACH TIKVA, Israel, Jan. 30, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference taking place virtually on February 11 - 12, 2025.
PolyPid to Participate in the Oppenheimer 35th Annual Healthcare Life Sciences Conference
Neutral
GlobeNewsWire
1 week ago
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
PETACH TIKVA, Israel, Jan. 29, 2025 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its fourth quarter and full-year 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, February 12, 2025. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
PolyPid to Report Fourth Quarter and Full-Year 2024 Financial Results and Operational Highlights on February 12, 2025
Positive
Benzinga
1 month ago
Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday
Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades and downgrades, please see our analyst ratings page.
Kemper To Rally More Than 25%? Here Are 4 Top Analyst Forecasts For Thursday
Neutral
GlobeNewsWire
1 month ago
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million
• 630 Patients Enrolled To Date; Enrollment Completion Now Expected in Q1 2025 with Top-line Results Anticipated in Q2 2025;
PolyPid Announces Positive Recommendation by DSMB to Continue Enrollment of Phase 3 SHIELD II Trial of D-PLEX₁₀₀ to 800 Patients with a Concurrent Private Placement of up to $41 Million
Neutral
GlobeNewsWire
1 month ago
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
PETACH TIKVA, Israel, Dec. 11, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced a new research and development collaboration with ImmunoGenesis, Inc. (“ImmunoGenesis”), a Houston-based clinical-stage biotechnology company developing science-driven immunotherapies. The collaboration focuses on the development of novel formulations utilizing PolyPid's experience with its proprietary PLEX Technology and ImmunoGenesis' potent STimulator of INterferon Genes (STING) agonist drug candidate to potentially enhance treatment for solid tumors.
PolyPid Announces Research and Development Collaboration with ImmunoGenesis Leveraging PLEX Technology to Enhance Cancer Immunotherapy
Neutral
GlobeNewsWire
2 months ago
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance
PETACH TIKVA, Israel, Nov. 29, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it has received a written notification (the "Notification Letter") from the Listing Qualifications staff of The Nasdaq Stock Market LLC (“Nasdaq”) notifying the Company that it is no longer in compliance with the minimum stockholders' equity requirement for continued listing on the Nasdaq Capital Market, listing Rule 5550(b)(1), due to its failure to maintain a minimum of $2,500,000 in stockholders' equity. In the Company's Form 6-K dated November 13, 2024, the Company reported stockholders' equity of approximately $2,158,000 as of September 30, 2024.
PolyPid Announces Receipt of Nasdaq Notification of Minimum Stockholders' Equity Non-Compliance
Neutral
Seeking Alpha
2 months ago
PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript
PolyPid Ltd. (NASDAQ:PYPD ) Q3 2024 Earnings Conference Call November 13, 2024 8:30 AM ET Company Participants Brian Ritchie - Investor Relations, LifeSci Advisors Dikla Czaczkes Akselbrad - Chief Executive Officer Ori Warshavsky - Chief Operating Officer, U.S. Jonny Missulawin - Chief Financial Officer Conference Call Participants Roy Buchanan - JMP Chase Knickerbocker - Craig-Hallum Operator Greetings, and welcome to the PolyPid Third Quarter 2024 Conference Call.
PolyPid Ltd. (PYPD) Q3 2024 Earnings Call Transcript
Neutral
GlobeNewsWire
3 months ago
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
PETACH TIKVA, Israel, Nov. 07, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD), (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that the Company's management will participate in investor meetings at the Craig-Hallum 15th Annual Alpha Select Conference on November 19, 2024, in New York, NY.
PolyPid to Participate in the Craig-Hallum 15th Annual Alpha Select Conference
Neutral
GlobeNewsWire
3 months ago
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024
PETACH TIKVA, Israel, Oct. 30, 2024 (GLOBE NEWSWIRE) -- PolyPid Ltd. (Nasdaq: PYPD) (“PolyPid” or the “Company”), a late-stage biopharma company aiming to improve surgical outcomes, today announced that it will report its third quarter 2024 financial results and operational highlights before the open of the U.S. financial markets on Wednesday, November 13, 2024. The Company will host a conference call and webcast at 8:30 AM Eastern Time to discuss the results and provide an update on business operations.
PolyPid to Report Third Quarter 2024 Financial Results and Operational Highlights on November 13, 2024
Neutral
GlobeNewsWire
3 months ago
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
SHIELD I Study is One of the Largest Phase 3 Trials in the Prevention of SSIs in Colorectal Resection Conducted in Over a Decade
PolyPid Announces Publication in International Journal of Surgery Highlighting Results of Phase 3 SHIELD I Trial of D-PLEX₁₀₀ in Prevention of Surgical Site Infections in Abdominal Colorectal Surgery
Charts implemented using Lightweight Charts™